Comparative Pharmacology
Head-to-head clinical analysis: HIVID versus ZIAGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIVID versus ZIAGEN.
HIVID vs ZIAGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIVID (zalcitabine) is a nucleoside analogue reverse transcriptase inhibitor (NRTI). It is phosphorylated intracellularly to its active triphosphate form, which competes with endogenous deoxycytidine triphosphate for incorporation into viral DNA, leading to chain termination and inhibition of HIV reverse transcriptase.
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI). It is converted intracellularly to carbovir triphosphate, which competes with dGTP for incorporation into viral DNA, causing chain termination and inhibition of HIV reverse transcriptase.
0.75 mg orally every 8 hours.
600 mg orally once daily, or 300 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life 3.5 hours (range 2.9-4.1 h), prolonged to 8-12 h in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 1.5–2 hours (mean 1.7 h); intracellular triphosphate half-life: 12–15 hours, supporting once-daily dosing
Renal: 75% as unchanged drug; fecal: 18% as metabolites; biliary: <5%
Renal (approximately 82% as unchanged drug and metabolites via glomerular filtration and active tubular secretion); biliary/fecal (minor, <2%)
Category C
Category C
Antiretroviral (NRTI)
Antiretroviral (NRTI)